Amneal Reaffirms 2024 Revenue Guidance Of $2.55B-$2.65B Versus Consensus Of $2.60B, With Adjusted EBITDA of $0.53-$0.63 Compared To Guidance Of $0.58
Amneal Reaffirms 2024 Revenue Guidance Of $2.55B-$2.65B Versus Consensus Of $2.60B, With Adjusted EBITDA of $0.53-$0.63 Compared To Guidance Of $0.58
Amneal Pharmaceuticals Sees 2024 Adj EPS 53c-Adj EPS 63c >AMRX
Amneal Pharmaceuticals Sees 2024 Adj EPS 53c-Adj EPS 63c >AMRX
Amneal Pharmaceuticals Q1 2024 Adj EPS $0.14 Beats $0.09 Estimate, Sales $659.191M Beat $619.033M Estimate
Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.09 by 55.56 percent. This is a 16.67 percent increase over earnings of
GUIDANCE: (AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63
06:01 AM EDT, 05/03/2024 (MT Newswires) -- GUIDANCE: (AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q1 Revenue $659.2M, Vs. Street Est of $619M
06:01 AM EDT, 05/03/2024 (MT Newswires) -- Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q1 Revenue $659.2M, vs. Street Est of $619M
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q1 EPS $0.14, Vs. Street Est of $0.09
06:01 AM EDT, 05/03/2024 (MT Newswires) -- Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q1 EPS $0.14, vs. Street Est of $0.09